Argos Therapeutics Inc (NASDAQ:ARGS) has been assigned a consensus rating of “Hold” from the six brokerages that are presently covering the stock. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $4.47.

A number of research analysts recently commented on the stock. Zacks Investment Research raised shares of Argos Therapeutics from a “hold” rating to a “buy” rating and set a $6.00 price target for the company in a report on Monday, January 16th. FBR & Co reissued a “buy” rating and issued a $13.00 price objective on shares of Argos Therapeutics in a research report on Tuesday, January 17th. Needham & Company LLC lowered shares of Argos Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, February 22nd. JMP Securities lowered shares of Argos Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 22nd. Finally, Stifel Nicolaus lowered shares of Argos Therapeutics from a “buy” rating to a “hold” rating and set a $1.40 price objective on the stock. in a research report on Wednesday, February 22nd.

An institutional investor recently raised its position in Argos Therapeutics stock. State Street Corp boosted its position in Argos Therapeutics Inc (NASDAQ:ARGS) by 11.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 177,494 shares of the biopharmaceutical company’s stock after buying an additional 18,625 shares during the period. State Street Corp owned approximately 0.43% of Argos Therapeutics worth $870,000 at the end of the most recent quarter. 15.25% of the stock is owned by institutional investors and hedge funds.

Argos Therapeutics (NASDAQ:ARGS) traded down 20.3034% during midday trading on Monday, reaching $0.4781. The company had a trading volume of 2,438,889 shares. The firm has a 50-day moving average price of $0.78 and a 200-day moving average price of $3.62. The company’s market capitalization is $19.77 million. Argos Therapeutics has a 52 week low of $0.31 and a 52 week high of $9.22.

TRADEMARK VIOLATION WARNING: “Argos Therapeutics Inc (ARGS) Receives $10.07 Consensus Target Price from Brokerages” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.watchlistnews.com/argos-therapeutics-inc-args-receives-10-07-consensus-target-price-from-brokerages/1205682.html.

Argos Therapeutics Company Profile

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

5 Day Chart for NASDAQ:ARGS

Receive News & Ratings for Argos Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.